Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05922501
Title Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (ISABELA)
Acronym ISABELA
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.